Universe Pharmaceuticals
Universe Pharmaceuticals' revenue fell 22.4% to $17.9 billion in fiscal 2025. Its operating margin was −16.3%, up from −34.8% a year earlier. Free cash flow was −$5.3 billion. The diluted share count rose 3174.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2019 to 2021, earnings per share grew 12.7% a year and net income 21.9% a year, as new shares raised the share count by 19% and diluted each share's earnings. Universe Pharmaceuticals then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0.0 | 5.7 | 5.3 | 30.9 | — |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 133.8x | −43.2x | −20.9x | −26.3x | −10.1x |
| Current ratio | 4.5x | 3.2x | 1.8x | 2.5x | 4.1x |
| Quick ratio | 4.3x | 3.0x | 1.6x | 2.5x | 3.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 80,387.1% | −70.9% | −52.2% |
| Altman Z'' | 1,498.16 | 3.87 | 7.37 |
| Accruals ratio | −15,203.4% | 2.3% | 2.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Universe Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Universe Pharmaceuticals | FY25 | −22.4% | −16.3% | −29.8% | — | — | — | |
| Teva Pharmaceuticals | FY25 | 4.3% | 12.5% | 6.7% | 10.5% | 4.2x | 8 | Compare |
| Viatris | FY25 | −3.0% | −18.6% | 13.6% | −7.0% | 96.5x | 4 | Compare |
| Bausch Health Companies | FY25 | 6.7% | 17.7% | 9.8% | 4.5% | 6.5x | 7 | Compare |
| GSK | FY25 | 4.1% | 24.3% | 19.6% | 23.9% | 1.4x | 8 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 32.3 | 23.0 | 17.9 |
| Revenue growth | — | −7.6% | 56.3% | −16.3% | 80,383.8% | −28.7% | −22.4% |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 10.3 | 6.1 | 6.3 |
| Research and development | 0.0 | 0.0 | 0.0 | 0.0 | 4.9 | 3.0 | 0.7 |
| Operating income | 0.0 | 0.0 | 0.0 | −0.0 | −4.0 | −8.0 | −2.9 |
| Net income | 0.0 | 0.0 | 0.0 | −0.0 | −6.6 | −8.7 | −3.7 |
| Diluted EPS (US$) | 2.82 | 2.82 | 3.58 | −1,309.11 | −1,089.21 | −626.96 | −8.06 |
| Diluted shares (millions) | 3 | 3 | 3 | 0 | 6 | 14 | 456 |
| Cash flow | |||||||
| Cash from operations | 0.0 | 0.0 | −0.0 | −0.0 | 1.1 | −9.5 | −5.1 |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 |
| Free cash flow | 0.0 | 0.0 | −0.0 | −0.0 | 1.1 | −9.7 | −5.3 |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Share buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stock-based compensation | — | — | — | — | — | — | — |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 0.0 | 0.0 | 0.0 | 5.7 | 5.3 | 30.9 | — |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 0.0 | 0.1 | 0.1 | 0.0 | 68.0 | 69.3 |
| Total liabilities | — | 0.0 | 0.0 | −35.3 | 0.0 | 22.5 | 13.2 |
| Shareholders' equity | 0.0 | 0.0 | 0.0 | 35.3 | 28.0 | 45.5 | 56.1 |
| Margins and ratios | |||||||
| Gross margin | 40.4% | 45.9% | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% |
| Operating margin | 29.4% | 33.4% | 28.3% | −17.5% | −12.3% | −34.8% | −16.3% |
| Net margin | 22.7% | 24.6% | 23.6% | −19.7% | −20.4% | −37.9% | −20.6% |
| Free cash flow margin | 39.5% | 19.8% | −5.2% | −3.5% | 3.3% | −42.2% | −29.8% |
| Rule of 40 (growth + FCF margin) | — | 12.2% | 51.1% | −19.8% | 80,387.1% | −70.9% | −52.2% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | 33.4% | −0.0% | −20.8% | −23.8% | −7.2% |
| Return on assets | — | — | 22.9% | −12.2% | −12,997.7% | −25.7% | −5.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — |